Fiix-prothrombin time monitoring improves warfarin anticoagulation outcome in atrial fibrillation: a systematic review of randomized trials comparing Fiix-warfarin or direct oral anticoagulants to standard PT-warfarin

被引:6
作者
Onundarson, P. T. [1 ,2 ]
Arnar, D. O. [1 ]
Lund, S. H. [2 ]
Gudmundsdottir, B. R. [1 ]
Francis, C. W. [3 ]
Indridason, O. S. [1 ]
机构
[1] Landspitali Natl Univ Hosp Iceland, Reykjavik, Iceland
[2] Univ Iceland, Fac Med, Reykjavik, Iceland
[3] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
关键词
Rivaroxaban; apixaban; edoxaban; dabigatran; warfarin; prothrombin time; meta analysis; systematic review; NORMALIZED RATIO CONTROL; STROKE PREVENTION; FACTOR-X; EFFICACY; SAFETY; DABIGATRAN; APIXABAN; ANTIGEN;
D O I
10.1111/ijlh.12537
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundMonitoring warfarin with Fiix-prothrombin time (Fiix-PT), which is only affected by coagulation factors II and X, stabilizes anticoagulation and reduces thromboembolism compared to PT/INR monitoring. We compared outcome in nonvalvular atrial fibrillation (NVAF) patients treated with Fiix-warfarin, direct oral anticoagulants (DOACs), or PT-warfarin. MethodsA systematic efficacy and safety assessment by retrieving data from the Fiix trial and the four major phase III DOAC trials in NVAF. Prespecified outcomes included stroke and systemic embolism (SSE), SSE and myocardial infarction (MI), major bleeding (MB), composite major vascular events (SSEMI and MB; CMVE), and deaths. We calculated relative risk, 95% CI, and 95% confidence limits (CL) for each outcome and performed meta-analysis using fixed- and random-effects modeling. ResultsThere were 613 and 628 observation years with Fiix-warfarin and PT-warfarin in the Fiix trial, and 70628 and 57962 with DOACs and PT-warfarin in DOAC trials. Populations were comparable although death rates were lower in the Fiix trial. Compared to pooled PT-warfarin, Fiix-warfarin reduced SSE (RR 0.54;95% CI 0.26-1.10/95% CL <1.00), SSEMI (0.51;0.26-0.99/<0.90), MB (RR 0.63;0.37-1.07/<0.99), and CMVE (RR 0.66;0.43-1.00/<0.94). Vascular death was lower (RR 0.13;0.04-0.47/<0.42). Compared to pooled DOACs, Fiix-warfarin consistently had lower point estimates for the RR for efficacy and safety, but only significant for lower death rates (vascular death RR 0.14;0.04-0.49/<0.43). Meta-analysis comparing Fiix-warfarin and DOACs with PT-warfarin consistently found Fiix-warfarin to have the lowest point estimates for efficacy. ConclusionMonitoring warfarin with Fiix-PT reduces risk of vascular events in NVAF patients as much as DOACs. Warfarin monitored with Fiix-PT is an improved anticoagulant.
引用
收藏
页码:78 / 90
页数:13
相关论文
共 25 条
[1]   CHRISTMAS DISEASE - A CONDITION PREVIOUSLY MISTAKEN FOR HAEMOPHILIA [J].
BIGGS, R ;
DOUGLAS, AS ;
MACFARLANE, RG ;
DACIE, JV ;
PITNEY, WR ;
MERSKEY, C ;
OBRIEN, JR .
BRITISH MEDICAL JOURNAL, 1952, 2 (4799) :1378-1382
[2]   INVESTIGATION Rivaroxaban: can we trust the evidence? [J].
Cohen, Deborah .
BMJ-BRITISH MEDICAL JOURNAL, 2016, 352
[3]   Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range [J].
Connolly, Stuart J. ;
Pogue, Janice ;
Eikelboom, John ;
Flaker, Gregory ;
Commerford, Patrick ;
Franzosi, Maria Grazia ;
Healey, Jeffrey S. ;
Yusuf, Salim .
CIRCULATION, 2008, 118 (20) :2029-2037
[4]   Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].
Connolly, Stuart J. ;
Ezekowitz, Michael D. ;
Yusuf, Salim ;
Eikelboom, John ;
Oldgren, Jonas ;
Parekh, Amit ;
Pogue, Janice ;
Reilly, Paul A. ;
Themeles, Ellison ;
Varrone, Jeanne ;
Wang, Susan ;
Alings, Marco ;
Xavier, Denis ;
Zhu, Jun ;
Diaz, Rafael ;
Lewis, Basil S. ;
Darius, Harald ;
Diener, Hans-Christoph ;
Joyner, Campbell D. ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151
[5]  
DUCKERT F, 1955, P SOC EXP BIOL MED, V90, P17
[6]  
FURIE B, 1984, BLOOD, V64, P445
[7]  
FURIE B, 1990, BLOOD, V75, P344
[8]   Edoxaban versus Warfarin in Patients with Atrial Fibrillation [J].
Giugliano, Robert P. ;
Ruff, Christian T. ;
Braunwald, Eugene ;
Murphy, Sabina A. ;
Wiviott, Stephen D. ;
Halperin, Jonathan L. ;
Waldo, Albert L. ;
Ezekowitz, Michael D. ;
Weitz, Jeffrey I. ;
Spinar, Jindrich ;
Ruzyllo, Witold ;
Ruda, Mikhail ;
Koretsune, Yukihiro ;
Betcher, Joshua ;
Shi, Minggao ;
Grip, Laura T. ;
Patel, Shirali P. ;
Patel, Indravadan ;
Hanyok, James J. ;
Mercuri, Michele ;
Vogelmann, O. ;
Gonzalez, C. ;
Ahuad Guerrero, R. ;
Rodriguez, M. ;
Albisu, J. ;
Rosales, E. ;
Allall, O. ;
Reguero, M. ;
Alvarez, C. ;
Garcia, M. ;
Ameriso, S. ;
Ameriso, P. ;
Amuchastegui, M. ;
Caceres, M. ;
Beloscar, J. ;
Petrucci, J. ;
Berli, M. ;
Budassi, N. ;
Valle, M. ;
Bustamante Labarta, G. ;
Saravia, M. ;
Caccavo, A. ;
Fracaro, V. ;
Cartasegna, L. ;
Novas, V. ;
Caruso, O. ;
Saa Zarandon, R. ;
Colombo, H. ;
Morandini, M. ;
Cuello, J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (22) :2093-2104
[9]  
Gomez-Outes Antonio, 2013, Thrombosis, V2013, P640723, DOI 10.1155/2013/640723
[10]   Apixaban versus Warfarin in Patients with Atrial Fibrillation [J].
Granger, Christopher B. ;
Alexander, John H. ;
McMurray, John J. V. ;
Lopes, Renato D. ;
Hylek, Elaine M. ;
Hanna, Michael ;
Al-Khalidi, Hussein R. ;
Ansell, Jack ;
Atar, Dan ;
Avezum, Alvaro ;
Cecilia Bahit, M. ;
Diaz, Rafael ;
Easton, J. Donald ;
Ezekowitz, Justin A. ;
Flaker, Greg ;
Garcia, David ;
Geraldes, Margarida ;
Gersh, Bernard J. ;
Golitsyn, Sergey ;
Goto, Shinya ;
Hermosillo, Antonio G. ;
Hohnloser, Stefan H. ;
Horowitz, John ;
Mohan, Puneet ;
Jansky, Petr ;
Lewis, Basil S. ;
Luis Lopez-Sendon, Jose ;
Pais, Prem ;
Parkhomenko, Alexander ;
Verheugt, Freek W. A. ;
Zhu, Jun ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (11) :981-992